Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | GRM2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | RIMKLA | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | DTL | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | SF3A2 | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
mRNA | ZDHHC7 | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
mRNA | DST | CTRPv2 | pan-cancer | AAC | -0.17 | 2e-06 |
mRNA | C11orf24 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
mRNA | EMX1 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-06 |
mRNA | ATP6V0E2 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-06 |
mRNA | TGIF2-C20orf24 | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |